CLAIMS

What is claimed is:

1. A compound of Formula (I):



(I)

or stereoisomers, tautomers, or salts thereof, wherein:

R is:



or

.

2. The compound according to claim 1, or stereoisomers, tautomers, or salts thereof, wherein said compound is:



.

3. The compound according to claim 1, or stereoisomers, tautomers, or salts thereof, wherein said compound is:



4. The compound according to claim 1, or stereoisomers, tautomers, or salts thereof, wherein said compound is:



5. The compound according to claim 1, or stereoisomers, tautomers, or salts thereof, wherein said compound is:



6. The compound according to claim 1, or stereoisomers, tautomers, or salts thereof, wherein said compound is:



7. A pharmaceutical composition comprising a compound according to any one of claims 1 to 6, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof; and a pharmaceutically acceptable carrier.

8. A compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, according to any one of claims 1 to 6 for use in the treatment of cancer.

9. The compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, for use according to claim 8, wherein said cancer is selected from cancer of the colon, gastric, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, renal cancer, cancer of the head and neck, lymphoma, leukemia, and melanoma.

10. The compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, for use according to claim 9 in combination with a second agent, wherein said second agent is selected from an antagonist of PD1/PD-L1 axis, an antagonist of CTLA4, a chemotherapeutic agent, radiation, or an anti-tumor vaccine.

11. A compound, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6 for use in treating cancer, wherein the compound, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof is capable of decreasing Ikaros, Helios, Aiolos, and Eos protein levels in cells, wherein said cells are to be contacted with said compound, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein

a) said Ikaros protein level is decreased by at least 30 %;
b) said Helios protein level is decreased by at least 50 %;
c) said Aiolos protein level is decreased by at least 30 %; and
d) said Eos protein level is decreased by at least 50 %.

12. Use of the compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, according to any one of claims 1 to 6 in the manufacture of a medicament for treating cancer.

13. The use according to claim 12, wherein said cancer is selected from cancer of the colon, gastric, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian

cancer, cervical cancer, renal cancer, cancer of the head and neck, lymphoma, leukemia, and melanoma.

14. The use according to claim 13, wherein the compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof are used in combination with a second agent, wherein said second agent is selected from an antagonist of PD1/PD-L1 axis, an antagonist of CTLA4, a chemotherapeutic agent, radiation, or an anti-tumor vaccine.

15. Use of the compound, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6 in the manufacture of a medicament for treating cancer, wherein the medicament is capable of decreasing Ikaros, Helios, Aiolos, and Eos protein levels in cells, wherein said cells are to be contacted with said compound, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein

a) said Ikaros protein level is decreased by at least 30 %;
b) said Helios protein level is decreased by at least 50 %;
c) said Aiolos protein level is decreased by at least 30 %; and
d) said Eos protein level is decreased by at least 50 %.

16. A compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, according to any one of claims 1 to 6 for use in therapy.